Search This Blog

Tuesday, January 21, 2020

Medicare for All would cut household income by 11%: Heritage study

Most Americans will pay much higher taxes and earn less income if Medicare for All becomes law, a new study by The Heritage Foundation states.
“How ‘Medicare for All’ Harms Working Americans” found 73.5 percent of Americans would shoulder financial hardships under the proposed universal health care system.
Most workers would pay 21.2 percent more in federal payroll taxes, bringing the rate to 36.5 percent for most workers. Average annual disposable income for U.S. households would decrease by an average of $5,671.
In addition to income taxes, most American workers pay 15.3 percent in payroll tax, 12.4 percentage points of which funds Social Security and 2.9 percentage points goes to Medicare. The new payroll tax of 36.5 percent would apply to every dollar earned, from the lowest-paid worker to the highest, the study states.
People who receive health insurance from their employer would be hit with an even bigger decrease in household income. Their disposable income loss would be $10,554 because they would lose the tax advantages from their employer insurance, which is currently untaxed. The study, released on November 19, finds 87.2 percent of households with employer-sponsored health insurance would be financially worse off.
All Income Groups Lose
Proponents of Medicare for All argue a government-run system will benefit consumers by costing less than what they have been paying for private insurance or health care services paid for out of pocket. That assumption is false, the study states.
“Our analysis finds that in order to fund such a program, it would be necessary for the federal government to impose substantial, broad-based taxes equal to 21.2 percent of all wage and salary income,” study authors Edmund Haislmaier and Jamie Hall write.
The 21.2 percent tax on workers would be necessary to fund a program that not only replaces employer-paid insurance but also insurance for workers with no health plans and the “additional spending that would result from the program stimulating increased use of medical care.”
In addition, the Medicare for All proposals offered by contenders for the Democrat presidential nomination would cover many services currently not covered by Medicare, such as long-term care, the study states.
Lower-income working families that currently get their health care through Medicaid or the Children’s Health Insurance Program would also lose, because they too would be subjected to higher taxes, the study finds. Haislmaier and Hall calculate these families’ average household income would decrease by $5,592 a year.
The authors used data from the 2016 Medical Expenditure Panel Survey of 12,704 households in making their calculations.
Edmund Haislmaier and Jamie Hall, “How ‘Medicare for All’ Harms Working Americans,” The Heritage Foundation, November 19, 2019: https://www.heartland.org/publications-resources/publications/how-medicare-for-all-harms-working-americans

Trovagene up 30% ahead of onvansertib data presentation

Nano cap Trovagene (TROV +29.7%) is up on modestly higher volume ahead of a presentation of Phase 1b/2 data on lead candidate onvansertib in KRAS-positive colorectal cancer at the ASCO GI Cancers Symposium this Saturday, January 25.

Annovis Bio sets IPO terms

Annovis Bio (ANVS) has filed a preliminary prospectus for an IPO of ~1.4M common shares at $6 – 8 per share. Underwriters’ over-allotment will be an additional ~214K shares.
Lead candidate is ANVS-401 for the potential treatment of Alzheimer’s and Parkinson’s diseases.

FDA approves Axonics’ neurostimulator programmer

Axonics Modulation Technologies (NASDAQ:AXNXannounces FDA approval of second-generation Programmer for its r-SNM System under a premarket approval (“PMA”) application supplement.
The new Programmer is used to program the Axonics external trial neurostimulator as well as the implantable neurostimulator in both the procedure and post-operative environments.

1Life Healthcare sets terms of upsized IPO

1Life Healthcare (ONEM) has filed a prospectus for its IPO of 17.5M common shares at $14 – 16 per share. Underwriters’ over-allotment will be an additional ~2.6M shares.
Gross proceeds should be ~$263M (midpoint), up from $100M filed a few weeks ago.

Novartis’ Mayzent OK’d in Europe for multiple sclerosis

As expected, the European Commission approves Novartis’ (NYSE:NVS) Mayzent (siponimod) for the treatment of adults with secondary progressive multiple sclerosis with active disease.
Two months ago, the advisory group CHMP adopted a positive opinion backing approval.

Bausch Health to drop Cipher’s Trulance

Cipher Pharmaceuticals (OTC:CPHRFreports that Bausch Health Companies (NYSE:BHC) has notified it that it intends to terminate its license agreement for constipation med Trulance (plecanatide) due to an undisclosed breach of certain provisions of the contract.
It previously disclosed that it is reviewing certain distribution partnerships in Canada and is in active discussions to sub-license Trulance to multiple parties. It intends to “vigorously challenge” BHC over its planned exit.
Cipher acquired exclusive rights in Canada from Synergy Pharmaceuticals in February 2018.